다음 MAP메이트™는 통합될 수 없습니다: -다른 분석 완충용액이 필요한 MAP메이트™. -인산 특이성 및 총 MAP메이트™ 조합, 예: 총 GSK3β 및 GSK3β(Ser 9). -PanTyr 및 자리 특이성 MAP메이트™, 예: Phospho-EGF 수용체 및 phospho-STAT1(Tyr701). -단일 표적(Akt, STAT3)를 위한 1개 이상의 1 phospho-MAP메이트™. - GAPDH 및 β-Tubulin은 panTyr를 포함하는 키트 또는 MAP메이트™와 통합될 수 없습니다.
Custom Premix Selecting "Custom Premix" option means that all of the beads you have chosen will be premixed in manufacturing before the kit is sent to you.
Catalogue Number
Ordering Description
Qty/Pack
List
이 제품은 즐겨찾기에 저장되었습니다.
종
패널 유형
선택하신 키트
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
96-Well Plate
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
다른 시약 추가 (MAP메이트 사용을 위해 완충용액과 검출 키트가 필요함)
수량
카탈로그 번호
주문 설명
포장 단위
기재 가격
48-602MAG
Buffer Detection Kit for Magnetic Beads
1 Kit
공간 절약 옵션 다수의 키트를 구매하시는 고객은 고용량 저장을 위해 키트 포장을 제거하고 비닐백에 담긴 멀티플레스 분석 구성품을 받아 저장 공간을 절약하도록 선택할 수 있습니다.
이 제품은 즐겨찾기에 저장되었습니다.
해당 제품은 고객님의 카트에 추가되었습니다.
이제 다른 키트를 사용자 지정하거나, 사전 혼합된 키트를 선택하거나, 결재하거나 또는 주문 도구를 종료할 수 있습니다.
534337
Sigma-AldrichHIV Inhibitor, CADA - Calbiochem
A cell-permeable macrocyle cyclotriazadisulfonamide derivative compound that inhibits HIV replication (IC50 = 300 nM to 3.3 µM) and entry into cells by blocking co-translational translocation of nascent CD4 across endoplasmic reticulum membranes. Its action appears to be highly selective in reducing the expression of human CD4 and it does not affect the level of any other cell surface marker studied. Does not affect CD4 mRNA levels in cells. Shown to be effective against HIV-1 subtypes A to H, AE, and O and human herpesvirus 7 (HHV-7; IC50, 300 nM to 1.5 µM) in T-cell lines and PBMCs. Also reported to block X4 HIV-1 NL4.3 and R5 SIVmac251 laboratory strains infection in human T cells. Can act synergistically with cellulose acetate phthalate (CAP) and other anti-HIV drugs to inhibit HIV-1 and SIV infections.
Catalogue Number
534337
Brand Family
Calbiochem®
Synonyms
1-Benzyl-7-methylene-5,9-ditosyl-5,9-diaza-azoniacyclododecan-1-ium chloride, CD4 Inhibitor, CADA
References
References
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246. Bell, T. W., et al. 2006. J. Med. Chem.49, 1291. Vermeire, K., et al. 2004. AIDS.18, 2115. Vermeire, K., et al. 2002. Virology.302, 342.
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246. Bell, T. W., et al. 2006. J. Med. Chem.49, 1291. Vermeire, K., et al. 2004. AIDS.18, 2115. Vermeire, K., et al. 2002. Virology.302, 342.
Data Sheet
Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.
Revision
28-July-2017 JSW
Synonyms
1-Benzyl-7-methylene-5,9-ditosyl-5,9-diaza-azoniacyclododecan-1-ium chloride, CD4 Inhibitor, CADA
Description
A cell-permeable macrocyle cyclotriazadisulfonamide derivative compound that inhibits HIV replication (IC50 = 300 nM to 3.3 µM) and entry into cells by blocking co-translational translocation of nascent CD4 across endoplasmic reticulum membranes. Its action appears to be highly selective in reducing the expression of human CD4 and it does not affect the level of any other cell surface marker studied. Does not affect CD4 mRNA levels in cells. Shown to be effective against HIV-1 subtypes A to H, AE, and O and human herpesvirus 7 (HHV-7; IC50, 300 nM to 1.5 µM) in T-cell lines and PBMCs. Also reported to block X4 HIV-1 NL4.3 and R5 SIVmac251 laboratory strains infection in human T cells. Can act synergistically with cellulose acetate phthalate (CAP) and other anti-HIV drugs to inhibit HIV-1 and SIV infections.
Form
White solid
Intert gas (Yes/No)
Packaged under inert gas
Chemical formula
C₃₁H₃₉N₃O₄S₂·HCl
Purity
≥98% by HPLC
Solubility
DMSO (10 mg/ml). Insoluble in water.
Storage
Protect from light
-20°C
Do Not Freeze
Ok to freeze
Special Instructions
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Toxicity
Standard Handling
References
Vermeire, K., et al. 2008. Curr. HIV Res.6, 246. Bell, T. W., et al. 2006. J. Med. Chem.49, 1291. Vermeire, K., et al. 2004. AIDS.18, 2115. Vermeire, K., et al. 2002. Virology.302, 342.